Executive Summary

Canada has a fragmented system with regard to drug pricing but the Patented Medicines Pricing Review Board (PMPRB) is the main responsible body for regulating prices across Canada, monitoring ex-factory price ceilings of patented products in Canada. They ensure that prices set by manufacturers are not excessive through international reference pricing, comparing product prices to those in US, UK, Germany, Switzerland, Sweden, France and Italy. This section takes you through the process for determining a price for a pharmceutical product in Canda.

Historically, prices for generic products have been amongst the highest in the world. All 13 provinces and territories, along with the federal government, have been working together through the pan-Canadian Pharmaceutical Alliance (pCPA), the generic drugs initiative to achieve greater value for brand-name and generic drugs for publicly funded drug programs.